Status:
UNKNOWN
Measurement of Circulating Tumor Cells in Prostate Cancer
Lead Sponsor:
Sormland County Council, Sweden
Collaborating Sponsors:
Karolinska Institutet
iCellate Medical
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18-125 years
Brief Summary
Can tumor cells and tumor DNA be sampled from blood samples from prostate cancer patients? Is it possible to understand the causal relationship between the occurrence of the tumor cells and the tumor ...
Detailed Description
Prostate cancer is the most common form of cancer in men and the second most deadly. Today's diagnostic methods and treatments are therefore obviously not adequate. In this study we will evaluate a ne...
Eligibility Criteria
Inclusion
- patients diagnosed with prostate cancer of moderate risk planned for prostatectomy with lymph node removal, or
- patients diagnosed with prostate cancer stage 3, or
- patients with diagnosed prostate cancer stage 4, or
- patients with diagnosed benign inflammatory prostatitis or other benign urological condition constituting age-matched, cancer free, controls
Exclusion
- Patients undergoing prostate cancer treatment (no prostate cancer treatment should be given to the patient before blood collection)
- Patients with previous malignancy
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04101305
Start Date
September 1 2019
End Date
December 1 2021
Last Update
September 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Malarsjukhuset
Eskilstuna, Sormland, Sweden, 631 88